Protect Your Bank Account Before It’s Too Late

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

Jay Venkatesan Biography and Net Worth

Insider of Angion Biomedica

Prior to Angion, Dr. Venkatesan served as President and Director of Alpine Immune Sciences (ALPN), which he co-founded as a Managing Partner of Alpine BioVentures. Previously, Dr. Venkatesan was the founder and portfolio manager of Ayer Capital, a global healthcare fund. Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed healthcare investments. He was also a consultant at McKinsey & Co. and a venture investor with Patricof & Co. Ventures (now Apax Partners). He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.

What is Jay Venkatesan's net worth?: The estimated net worth of Jay Venkatesan is at least $0.00 as of May 24th, 2022. Dr. Venkatesan owns 172,145 shares of Angion Biomedica stock worth more than $0 as of April 24th. This net worth evaluation does not reflect any other investments that Dr. Venkatesan may own. Additionally, Dr. Venkatesan receives an annual salary of $619,880.00 as Insider at Angion Biomedica. Learn More about Jay Venkatesan's net worth.
How old is Jay Venkatesan?: Dr. Venkatesan is currently 51 years old. There are 2 older executives and no younger executives at Angion Biomedica. Learn More on Jay Venkatesan's age.
What is Jay Venkatesan's salary?: As the Insider of Angion Biomedica Corp., Dr. Venkatesan earns $619,880.00 per year. Learn More on Jay Venkatesan's salary.
How do I contact Jay Venkatesan?: The corporate mailing address for Dr. Venkatesan and other Angion Biomedica executives is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. Angion Biomedica can also be reached via phone at 415-655-4899 and via email at [email protected]. Learn More on Jay Venkatesan's contact information.
Has Jay Venkatesan been buying or selling shares of Angion Biomedica?: Jay Venkatesan has not been actively trading shares of Angion Biomedica during the past quarter. Most recently, on Tuesday, May 24th, Jay Venkatesan bought 3,220 shares of Angion Biomedica stock. The stock was acquired at an average cost of $12.40 per share, with a total value of $39,928.00. Following the completion of the transaction, the insider now directly owns 172,145 shares of the company's stock, valued at $2,134,598. Learn More on Jay Venkatesan's trading history.
Who are Angion Biomedica's active insiders?: Angion Biomedica's insider roster includes Itzhak Goldberg (Insider), John Neylan (Insider), Jennifer Rhodes (Insider), and Jay Venkatesan (Insider). Learn More on Angion Biomedica's active insiders.

Jay Venkatesan Insider Trading History at Angion Biomedica

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/24/2022	Buy	3,220	$12.40	$39,928.00	172,145
5/20/2022	Buy	5,000	$12.30	$61,500.00	168,925
12/27/2021	Buy	6,690	$25.50	$170,595.00
12/16/2021	Buy	2,788	$25.50	$71,094.00
2/9/2021	Sell	15,917	$160.00	$2,546,720.00

Jay Venkatesan Buying and Selling Activity at Angion Biomedica

Angion Biomedica Company Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Today's Range

Now: N/A

50 Day Range

MA: $6.48

$1.00

$10.00

2 Week Range

Now: N/A

Volume

224,800 shs

Average Volume

86,718 shs

Market Capitalization

$30.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Protect Your Bank Account Before It’s Too Late

From Weiss Ratings | Ad